Management of acute BTH events with intensive pegcetacoplan treatment in the OLE study∗
| Patient . | Sex . | Potential CAC† . | Management of acute BTH event . | Concomitant anticomplement treatment . | Concomitant RBC transfusion . | Subsequent rounds of intensive treatment‡ . | LDH (U/L) prior to event§ . | LDH (U/L) at day 1 . | LDH (U/L) at day 2 . | LDH (U/L) at day 7-12¦ . | LDH (U/L) at day 14-19‖ . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Female | Nasopharyngitis | IV | No | No | No | 625 | 2615 | 1802 | 469 | 617 |
| 2 | Female | Unexplained | SC | No | No | No | 334 | 1882 | 1607 | 272 | 176 |
| 3 | Female | Respiratory infection | SC | No | Yes | Yes | 224 | 3496¶ | NR | 954 | 2102 |
| 4 | Female | Unexplained | IV | No | No | Yes | 793 | 1425 | 1054 | 357 | 271 |
| 5 | Female | COVID-19 vaccination | SC | No | No | No | 229 | 976 | 1129 | 401 | 157 |
| 6 | Male | Left groin abscess | SC | No | No | No | 268 | 436 | 448 | 182 | 144 |
| 7 | Male | COVID-19 and meningococcal vaccination | IV | No | No | No | 201 | 1234 | 869 | 260 | 173 |
| 8 | Male | Unexplained | SC | No | No | No | 398 | 1335¶ | 1261 | 438 | 266 |
| 9 | Male | Unexplained | SC | No | No | No | 662 | 1961 | 1840 | 499 | 326 |
| 10 | Male | Unexplained | SC | Eculizumab 900 mg | No | No | 193¶ | 1708¶ | 1849¶ (day 3) | 1517¶ | 359¶ |
| 11 | Male | Unexplained | IV | No | Yes | Yes | 456 | 5865 | 3868 | 1173 | 958 |
| 12 | Male | COVID-19 vaccination | SC | No | Yes | Yes | 273 | 6339¶ | 6767¶ | 841 | 452 |
| 13 | Male | Unexplained | SC | No | Yes | No | 402 | 751 | 662 | 397 | 267 |
| Patient . | Sex . | Potential CAC† . | Management of acute BTH event . | Concomitant anticomplement treatment . | Concomitant RBC transfusion . | Subsequent rounds of intensive treatment‡ . | LDH (U/L) prior to event§ . | LDH (U/L) at day 1 . | LDH (U/L) at day 2 . | LDH (U/L) at day 7-12¦ . | LDH (U/L) at day 14-19‖ . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Female | Nasopharyngitis | IV | No | No | No | 625 | 2615 | 1802 | 469 | 617 |
| 2 | Female | Unexplained | SC | No | No | No | 334 | 1882 | 1607 | 272 | 176 |
| 3 | Female | Respiratory infection | SC | No | Yes | Yes | 224 | 3496¶ | NR | 954 | 2102 |
| 4 | Female | Unexplained | IV | No | No | Yes | 793 | 1425 | 1054 | 357 | 271 |
| 5 | Female | COVID-19 vaccination | SC | No | No | No | 229 | 976 | 1129 | 401 | 157 |
| 6 | Male | Left groin abscess | SC | No | No | No | 268 | 436 | 448 | 182 | 144 |
| 7 | Male | COVID-19 and meningococcal vaccination | IV | No | No | No | 201 | 1234 | 869 | 260 | 173 |
| 8 | Male | Unexplained | SC | No | No | No | 398 | 1335¶ | 1261 | 438 | 266 |
| 9 | Male | Unexplained | SC | No | No | No | 662 | 1961 | 1840 | 499 | 326 |
| 10 | Male | Unexplained | SC | Eculizumab 900 mg | No | No | 193¶ | 1708¶ | 1849¶ (day 3) | 1517¶ | 359¶ |
| 11 | Male | Unexplained | IV | No | Yes | Yes | 456 | 5865 | 3868 | 1173 | 958 |
| 12 | Male | COVID-19 vaccination | SC | No | Yes | Yes | 273 | 6339¶ | 6767¶ | 841 | 452 |
| 13 | Male | Unexplained | SC | No | Yes | No | 402 | 751 | 662 | 397 | 267 |
BTH, breakthrough hemolysis; CAC, complement-amplifying condition; COVID-19, coronavirus disease 2019; NR, not reported; RBC, red blood cell.
In cases of multiple acute BTH events, the data relate to the first acute BTH event. Day 1 of intensive treatment may not necessarily mean day 1 of hemolysis event, therefore, LDH levels before event may not represent baseline values.
Potential CAC within 30 days before intensive pegcetacoplan treatment.
To manage subsequent acute BTH events additional doses of intensive pegcetacoplan IV were administered.
Most recent available measurement before intensive pegcetacoplan treatment.
Dependent on available measurement 7 to 12 days and 14 to 19 days after intensive pegcetacoplan treatment, respectively.
Data from local laboratory; laboratory values from local laboratories were standardized to central laboratory based on normal ranges from respective laboratories.